about 95% of the referrals to colposcopic biopsies based on cotesting by cytology and HC2 assay in the United States have been found to be unnecessary, regardless of the patients' age, 4 since a combined HC2+ and atypical squamous cells of undetermined significance cytology result only has a 3.2% positive predictive value for CIN2/3 detection. 5 For patient safety, health care providers must accept the truth that the HPV test is a virology test, not a test for predicting cancer. 6 The authors compared the results of HPV DNA detection by the Cervista HPV HR assay and those by a reference standard consisting of "combined detection of HPV DNA by the Hybrid Capture 2 (HC2) assay and DNA sequencing of the polymerase chain reaction (PCR)-amplified human papillomavirus (HPV) DNA," summarized in Table 1 ), the use of poorly performing or unvalidated HPV tests for clinical decision making is exactly the main focus of this and our prior commentary. Such tests have the potential for significant physical and psychosocial harm due to falsepositive and false-negative results. 3, 4 False-positive results may result in unnecessary referral of women to colposcopy, potentially resulting in treatment, which has important negative reproductive consequences such as preterm delivery and perinatal mortality. 3 It may also unnecessarily stigmatize some women by labeling them as having HPV infections although they are at very low risk of cervical precancer and cancer. False-negative results can put women with a precancerous lesion at risk for invasive cervical cancer.
Dr Lee fails to recognize that the purpose of screening tests is to reliably rule out disease in a mostly healthy population, rather than to diagnose the small percentage with disease, which is accomplished in the clinical follow-up of the screen-positive population. HPV DNA testing does this very well: a negative HPV test connotes excellent safety against cervical precancer, invasive cervical cancer, and even cervical cancer-related death for many years. [5] [6] [7] Dr Lee is correct that a positive HPV test does not indicate the presence of a precancerous lesion, which is why triage of the HPV+ test result using a more specific biomarker of risk is necessary. The current method of triage of an HPV+ result is to use cervical cytology, which would refer the same population of women to colposcopy as cytology-only screening but recommends increased surveillance of HPV+ women with normal cytology (HPV+/Cyto-) who are at an elevated risk of cervical precancer and cancer compared with the general populace. Validated HPV genotyping for the most carcinogenic HPV genotypes, HPV-16 and HPV-18, may be useful for referring HPV+/Cyto-women at higher risk immediately to colposcopy. 8 In the future, to increase specificity for cervical precancer and cancer, screening programs may incorporate p16 INK4a immunocytochemical studies 9 and 1-year HPV persistence, 10 
be achieved by the pool of other HPV genotypes. 10, 11 Whether HPV DNA tests like the Hybrid Capture 2 (HC2; Qiagen, Gaithersburg, MD) are "virology" tests is a semantic point. 13 Retrospective analyses have shown that raising the cutpoint to 2.0 rlu/pc may increase the accuracy of HC2, 14 perhaps in part by reducing the crossreactivity with some noncarcinogenic HPV genotypes. 15 Yet, HC2 or any other HPV DNA test does not perfectly distinguish between benign and clinically important HPV infections. That is why not all HPV+ women are referred immediately to colposcopy. 8 In our most recent commentary, 1 we contrasted the performance of HC2 with the next HPV DNA test that was recently approved by the FDA, Cervista (Hologic, Bedford, MA), as an example of the potential dangers of excessive analytic sensitivity. The evidence presented in the manufacturer's package insert suggested that the use of Cervista would result in excessive positivity in routine screening. Given that HC2 has consistently demonstrated sensitivity of more than 90%, 4 it seems unlikely that increasing the analytic sensitivity for HPV DNA will do much to increase the clinical sensitivity for cervical precancer but will drastically hurt the clinical specificity of a test. By using the data from the manufacturer's package insert, we illustrated that the use of Cervista in cervical cancer screening might label 2-to 4-fold more women as HPV+ without any evidence of benefit, ie, improved clinical sensitivity. Such an increase in HPV+ test results will only result in stigmatizing more women and, ultimately, referring more women to colposcopy and probably leading to more unnecessary treatments. It is also noteworthy that the age-group prevalence of Cervista HPV+ results did not sharply decline with age, as expected in the United States, suggesting that Cervista positivity may not be specific for HPV DNA.
Dr Lee cites a single article 16 on the positive predictive value (PPV) of HPV testing among women 50 years and older with atypical squamous cell of undetermined significance (ASC-US) as evidence of the nonspecificity and lack of usefulness of HPV DNA testing. There is a wealth of evidence, including data from several clinical trials, that the PPV of HPV testing among women with ASC-US is approximately 20% for CIN 2+ and 10% for CIN 3+. 4, 17, 18 HPV DNA testing is now well proven and accepted as a triage test for ASC-US cytology, 8 distinguishing women at risk of CIN 2+ that is comparable to women with cytologic findings of low-grade squamous intraepithelial lesion who need colposcopy from women who have very low risk of CIN 2+ and do not need colposcopy. The low PPV in the cited article is easily understood based on our current understanding of HPV natural history and cervical carcinogenesis 19 : women 50 years and older are approximately 20 to 25 years older than the peak age of CIN 2/CIN 3 in the United States. 20 Finally, Dr Lee misrepresents our presentation of the paired results by Cervista and a combination of HC2 and PCR sequencing testing on a subset of specimens from the Cervista premarketing approval trial. A fraction of Cervista positives (10/94 [11%]) were judged as indeterminate by the combination of HC2 and PCR sequencing testing because the results were discordant (positive/negative or negative/ positive). We were not privy to distribution of discordant results so cannot speculate as to which test was negative. However, even if we maximized the analytic sensitivity of the combination of HC2 and PCR sequencing (which will have a greater analytic sensitivity than PCR sensitivity alone) by treating either or both positive as positive (and, therefore, reclassifying the indeterminates as positive), Cervista was still much more likely to test positive than the combined testing (odds ratio, 6.7; 95% confidence interval, 3.4-15 
